Company / Operating Income
Inhibrx Biosciences, Inc. Operating Income History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$135.0M
FY2025
5-year range
-$219.2M / -$135.0M
FY2023-FY2025
Trend
+38.4%
vs FY2024
Sector context
#106 of 204
Health Care
What the data says
At -$135M, Inhibrx Biosciences, Inc.'s operating income ranks #106 of 204 in the Health Care sector. Improved from -$219M to -$135M over the past 2 years.
Based on SEC 10-K filings.
-$135M in FY2025.
Improved from -$219M to -$135M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#106 of 204 in Health CareTop 52% of 204This company -$135.0M Sector average $107.7M
▼
-225.3% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 38.4% year-over-year.
- Ranks #106 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$135.0M | +38.4% |
| FY2024 | -$219.2M | +0.0% |
| FY2023 | -$219.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026